Nivolumab vs Rituximab
Nivolumab vs Rituximab: Overview
This comparison examines the pharmacological differences between Nivolumab and Rituximab.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.
Pharmacokinetics
Half-life: Nivolumab β 27 days; Rituximab β 22 days.
Chemical Properties
Type: Nivolumab β Antibody; Rituximab β Antibody.